Yurpeak 2.5 mg KwikPen

What Is Yurpeak 2.5 mg KwikPen?

Yurpeak 2.5 mg KwikPen is a prescription injectable medicine containing tirzepatide, marketed by Cipla Limited in India in collaboration with Eli Lilly and Company. It belongs to a class of medicines known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists.

It is designed for once-weekly subcutaneous administration and is available in a multi-dose, prefilled KwikPen device. Yurpeak is prescribed as part of a comprehensive treatment plan for eligible adults with type 2 diabetes or for chronic weight management in adults meeting the approved BMI criteria.

Yurpeak 2.5 mg KwikPen Uses

Yurpeak contains tirzepatide, which acts on two important incretin hormone receptors involved in glucose regulation and appetite control.

Its approved uses in India include:

Type 2 Diabetes Management: Helps improve blood glucose control in adults with insufficiently controlled type 2 diabetes, alongside diet and exercise. It may be prescribed alone when metformin is unsuitable or alongside other diabetes medicines.

Chronic Weight Management: Used alongside a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related health condition, such as hypertension, dyslipidaemia or type 2 diabetes.

Treatment suitability must be assessed by a qualified healthcare professional.

How Does Yurpeak (Tirzepatide) Work?

Tirzepatide activates both GIP and GLP-1 receptors, which play important roles in metabolic regulation.

It works through several mechanisms:

Enhances glucose-dependent insulin secretion.

Helps regulate glucagon secretion.

Slows gastric emptying, particularly after treatment initiation.

Influences appetite regulation and food intake.

Together, these actions help improve blood glucose regulation and support weight management in eligible patients.

Yurpeak 2.5 mg Dosage and Administration

Yurpeak 2.5 mg is generally used as the initial treatment strength to help patients adjust to tirzepatide therapy. The subsequent dose and treatment duration are determined by the prescribing physician according to individual response and tolerability.

The medicine is administered once weekly as a subcutaneous injection, typically into the abdomen, thigh or upper arm.

Important administration precautions:

Follow the instructions provided with the KwikPen.

Use a new compatible needle for each injection.

Never share the pen with another person.

Rotate injection sites as instructed.

Do not change the dose or injection schedule without medical advice.

Each KwikPen is designed to deliver four fixed weekly doses.

Possible Side Effects of Yurpeak

Like other prescription medicines, Yurpeak may cause adverse reactions. Commonly reported side effects of tirzepatide include:

Nausea and vomiting

Diarrhoea or constipation

Reduced appetite

Abdominal discomfort

Indigestion

Less common but potentially serious complications include pancreatitis, gallbladder problems, dehydration-related kidney complications and serious allergic reactions.

Seek immediate medical attention if you experience severe or persistent abdominal pain, difficulty breathing or signs of a serious allergic reaction.

Safety Precautions and Storage

Inform your doctor about your medical history and all medicines you currently take, particularly insulin or sulfonylureas, because combining these medicines may increase the risk of hypoglycaemia.

Discuss pregnancy, breastfeeding, previous pancreatitis, gallbladder disease, gastrointestinal conditions and any planned surgery with your healthcare professional before starting treatment.

Store Yurpeak in a refrigerator at 2°C–8°C before use. Do not freeze the medicine. Follow the product-specific patient leaflet for in-use storage conditions and expiry after first use.

Frequently Asked Questions

1. Is Yurpeak 2.5 mg KwikPen used for weight management?

Yes. It is approved for chronic weight management in eligible adults when combined with a reduced-calorie diet and increased physical activity.

2. Is Yurpeak a prescription medicine?

Yes. Yurpeak is a prescription medicine and should only be used under medical supervision.

3. How often is Yurpeak administered?

It is administered once weekly, according to the prescribed treatment schedule.

4. Can Yurpeak be used without dietary changes?

No. For approved weight management use, it should be combined with a reduced-calorie diet and increased physical activity.

Medical Disclaimer: This information is intended for educational purposes and does not replace professional medical advice, diagnosis or treatment. Always consult a qualified healthcare professional and read the approved prescribing information before using Yurpeak.

https://www.lilly.com/in/news/press-releases/lilly-and-cipla-sign-a-distribution-and-promotion-agreement-for-yurpeak-tirzepatide-in-india?utm_source=chatgpt.com